(Q44655643)

English

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

scientific article published on November 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 December 2017

0 references

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets (English)

1 reference

Europe PubMed Central

5 December 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

insulin therapy

1 reference

based on heuristic

inferred from title

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

internal medicine

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

author name string

P. Hollander

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617226

1 April 2024

R. Ratner

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617226

1 April 2024

M. Fineman

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617226

1 April 2024

S. Strobel

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617226

1 April 2024

L. Shen

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617226

1 April 2024

D. Maggs

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617226

1 April 2024

O. Kolterman

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617226

1 April 2024

C. Weyer

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14617226

1 April 2024

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14617226

1 April 2024

publication date

1 November 2003

1 reference

Europe PubMed Central

5 December 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1463-1326.2003.00295.x

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1463-1326.2003.00295.x/fullpdf

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

5 December 2017

5

1 reference

Europe PubMed Central

5 December 2017

6

1 reference

Europe PubMed Central

5 December 2017

408-414

1 reference

Europe PubMed Central

5 December 2017

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00295.X

21 January 2018

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00295.X

21 January 2018

Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00295.X

21 January 2018

Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00295.X

21 January 2018

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00295.X

21 January 2018

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00295.X

21 January 2018

Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00295.X

21 January 2018

Glycemic control in diabetes mellitus: have changes in therapy made a difference?

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00295.X

21 January 2018

In search of normoglycaemia in diabetes: controlling postprandial glucose

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2003.00295.X

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

2

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Combination therapies with insulin in type 2 diabetes

6

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

The medical management of hyperglycemia over a 10-year period in people with diabetes.

7

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

9

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Dose-response for glucagonostatic effect of amylin in rats

12

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone

14

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

20

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

23

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

27

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Standards of medical care for patients with diabetes mellitus

28

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Inhibition of central amylin signaling increases food intake and body adiposity in rats

31

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Amylin decreases food intake in mice

32

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Amylin, food intake, and obesity

33

1 reference

10.1046/J.1463-1326.2003.00295.X

https://api.crossref.org/works/10.1046/J.1463-1326.2003.00295.X

1 April 2024

Identifiers

10.1046/J.1463-1326.2003.00295.X

1 reference

Europe PubMed Central

5 December 2017

1 reference

Europe PubMed Central

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44655643&oldid=2118757300"